Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Hexima Limited
  6. Summary
    HXL   AU0000111932

HEXIMA LIMITED

(HXL)
End-of-day quote. End-of-day quote Australian Stock Exchange - 12/03
0.4 AUD   +15.94%
12/01Hexima Names New Chief Development Officer
MT
12/01HEXIMA : CEO's Presentation
PU
12/01Hexima Limited Announces Cessation of Marilyn Anderson as Executive Director
CI
 SummaryChartsNewsCompanyFinancials 
Quotes 5-day view   End-of-day quote. End-of-day quote Australian Stock Exchange
11/29/2021 11/30/2021 12/01/2021 12/02/2021 12/03/2021 Date
0.34 0.34 0.33 0.345 0.4 Last
102109 185763 62798 27276 136916 Volume
+4.62% 0.00% -2.94% +4.55% +15.94% Change
Estimated financial data (e)
Sales 2020 2,49 M 1,75 M 1,75 M
Net income 2020 -3,63 M -2,54 M -2,54 M
Net Debt 2020 1,66 M 1,17 M 1,17 M
P/E ratio 2020 -
Yield 2020 -
Sales 2021 4,08 M 2,87 M 2,87 M
Net income 2021 -6,87 M -4,82 M -4,82 M
Net cash position 2021 3,39 M 2,38 M 2,38 M
P/E ratio 2021 -2,77x
Yield 2021 -
Capitalization 61,4 M 43,1 M 43,1 M
EV / Sales 2020 -
EV / Sales 2021 4,62x
Nbr of Employees -
Free-Float 55,7%
More Financials
Company
Hexima Limited is an Australia-based clinical stage biotechnology company. The Company is engaged in the research and development of defensin peptides for applications as human therapeutics. The CompanyÔÇÖs lead product candidate, pezadeftide applied in a topical formulation, is a potential new prescription treatment for toenail fungal infections or onychomycosis. pezadeftide is under Australian Phase IIb clinical... 
More about the company
All news about HEXIMA LIMITED
12/01Hexima Names New Chief Development Officer
MT
12/01HEXIMA : CEO's Presentation
PU
12/01Hexima Limited Announces Cessation of Marilyn Anderson as Executive Director
CI
12/01Hexima Limited Announces Appointment of Nancy Sacco as Chief Development Officer
CI
11/25Hexima Completes Oversubscribed Share Purchase Plan
MT
11/25HEXIMA : Application for quotation of securities - HXL
PU
10/05Hexima Limited Announces Company Secretary Change
CI
09/253,559,437 Ordinary Shares of Hexima Limited are subject to a Lock-Up Agreement Ending o..
CI
08/31Jake Nunn Joins Board of Hexima Limited as Non-Executive Director, effective 1 Septembe..
CI
08/27HEXIMA : 2021áAnnual Financial Report
PU
08/27Hexima Limited Reports Earnings Results for the Full Year Ended June 30, 2021
CI
08/27Hexima Limited Auditor Raises 'Going Concern' Doubt
CI
08/24HEXIMA : Secures Chinese Patent for Fungal Nail Infection Treatment; Shares Surge 12%
MT
08/18Hexima Limited Announces Design Patent for Pezadeftide Commercial Packaging
CI
07/25Hexima Limited Announces Completion of Enrolment in Phase IIb Clinical Trial
CI
More news
News in other languages on HEXIMA LIMITED

- No features available -

More news
Chart HEXIMA LIMITED
Duration : Period :
Hexima Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Michael Douglas Arthur Aldridge CEO, Non-Independent Non-Executive Director & MD
Jonathan West Non-Executive Chairman
Marilyn Ann Anderson Chief Scientific Officer
Yolanda Gaspar Head-Clinical Operations
Nicole Louise van der Weerden Chief Operating Officer & Executive Director
Sector and Competitors
1st jan.Capi. (M$)
HEXIMA LIMITED116.22%43
MODERNA, INC.193.60%124 359
LONZA GROUP AG25.98%58 058
IQVIA HOLDINGS INC.46.05%49 991
SEAGEN INC.-13.93%27 564
CELLTRION, INC.-41.36%24 298